Vitamin D supplementation for cystic fibrosis
- PMID: 24823922
- DOI: 10.1002/14651858.CD007298.pub4
Vitamin D supplementation for cystic fibrosis
Abstract
Background: Cystic fibrosis (CF) is a genetic disorder with multiorgan effects. In a subgroup with pancreatic insufficiency malabsorption of the fat soluble vitamins (A, D, E, K) may occur. Vitamin D is involved in calcium homeostasis and bone mineralisation and may have extraskeletal effects. This review examines the evidence for vitamin D supplementation in cystic fibrosis.
Objectives: To assess the effects of vitamin D supplementation on the frequency of vitamin D deficiency, respiratory outcomes and vitamin D toxicity in the cystic fibrosis population.
Search methods: We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Trials Register comprising references identified from comprehensive electronic database searches and handsearches of relevant journals and abstract books of conference proceedings.Date of the most recent search: 08 July 2013.
Selection criteria: Randomised and quasi-randomised controlled studies of vitamin D supplementation compared to placebo in the cystic fibrosis population regardless of exocrine pancreatic function.
Data collection and analysis: Both authors independently assessed the risk of bias of each included study and extracted outcome data (from published study information) for assessment of bone mineralization, growth and nutritional status, frequency of vitamin D deficiency, respiratory status, quality of life and adverse events.
Main results: Six studies (239 participants) are included, although only three studies provided data from 69 adults and children with cystic fibrosis for analysis. One study compared a single high dose of vitamin D (250,000 IU) to placebo at the time of hospital admission with a respiratory exacerbation in 30 pancreatic insufficient adults with cystic fibrosis. The second study compared supplemental 800 international units (IU) vitamin D and placebo for 12 months in 30 osteopenic pancreatic insufficient adults; both groups continued 900 IU vitamin D daily. The third study compared supplemental 1 g calcium alone, 1600 IU vitamin D alone, 1600 IU vitamin D and 1 g calcium and placebo in a double-blind randomised cross-over study; only nine children who completed both vitamin D and placebo groups after six-months supplementation and a three-month washout period are included; pancreatic sufficiency or disease status of participants are not defined. The studies are not directly comparable due to differences in supplementation, outcome reporting and possibly participant characteristics (e.g. severity of lung disease, growth and nutrition, pancreatic sufficiency).The only outcome for which we could combine data from more than two studies was 25-hydroxyvitamin D levels; patients receiving vitamin D supplementation had significantly higher levels, mean difference 7.24 ng/ml (95% confidence interval 5.01 to 9.46). However, ironically one study reported 1,25(OH)2D with levels significantly favouring the placebo group, mean difference -30.30 pmol/ml (95% confidence interval -59.89 to -0.71). Bone mineral density was measured in two studies; both described no significant change between groups. There were no adverse events in any study.The remaining three studies are published as abstracts only and did not provide data for analysis. These abstracts include: a report of pre-intervention data in a study comparing daily calcitriol (0.25 or 0.5 micrograms) with placebo in pancreatic insufficient children and young adults; an interim report of a double-blind randomised control study comparing 5000 IU vitamin D daily for 12 weeks during winter in 67 adult cystic fibrosis patients; and a comparison of the effect of three months of vitamin D supplementation (dose not specified) with placebo on bone mineral density in 42 children with cystic fibrosis and low bone mineral density.Risk of bias was highly variable between all studies. Only one study had a low risk of bias for the five main criteria (random sequence generation, allocation, blinding, attrition and reporting). The rest of the studies had unclear or high risks of bias. Two studies had a low risk of bias for blinding and another two studies for attrition bias. In the studies published as abstracts, assessment of the risks of bias was uncertain in many aspects.
Authors' conclusions: In patients receiving vitamin D supplementation, 25-hydroxyvitamin D levels are significantly higher. However, there is no evidence of clinical benefit or harm in the limited number of small-sized published studies. Adherence to relevant cystic fibrosis guidelines on vitamin D supplementation should be considered until further evidence is available.
Update of
-
Vitamin D supplementation for cystic fibrosis.Cochrane Database Syst Rev. 2012 Apr 18;(4):CD007298. doi: 10.1002/14651858.CD007298.pub3. Cochrane Database Syst Rev. 2012. Update in: Cochrane Database Syst Rev. 2014 May 14;(5):CD007298. doi: 10.1002/14651858.CD007298.pub4. PMID: 22513949 Updated. Review.
Similar articles
-
Vitamin D supplementation for sickle cell disease.Cochrane Database Syst Rev. 2020 May 28;5(5):CD010858. doi: 10.1002/14651858.CD010858.pub3. Cochrane Database Syst Rev. 2020. PMID: 32462740 Free PMC article.
-
Omega-3 fatty acid supplementation for cystic fibrosis.Cochrane Database Syst Rev. 2020 Apr 10;4(4):CD002201. doi: 10.1002/14651858.CD002201.pub6. Cochrane Database Syst Rev. 2020. PMID: 32275788 Free PMC article.
-
Vitamin D supplementation for sickle cell disease.Cochrane Database Syst Rev. 2017 Jan 20;1(1):CD010858. doi: 10.1002/14651858.CD010858.pub2. Cochrane Database Syst Rev. 2017. Update in: Cochrane Database Syst Rev. 2020 May 28;5:CD010858. doi: 10.1002/14651858.CD010858.pub3. PMID: 28105733 Free PMC article. Updated. Review.
-
Vitamin D supplementation for cystic fibrosis.Cochrane Database Syst Rev. 2012 Apr 18;(4):CD007298. doi: 10.1002/14651858.CD007298.pub3. Cochrane Database Syst Rev. 2012. Update in: Cochrane Database Syst Rev. 2014 May 14;(5):CD007298. doi: 10.1002/14651858.CD007298.pub4. PMID: 22513949 Updated. Review.
-
Vitamin D supplementation for cystic fibrosis.Cochrane Database Syst Rev. 2009 Oct 7;(4):CD007298. doi: 10.1002/14651858.CD007298.pub2. Cochrane Database Syst Rev. 2009. Update in: Cochrane Database Syst Rev. 2012 Apr 18;(4):CD007298. doi: 10.1002/14651858.CD007298.pub3. PMID: 19821402 Updated. Review.
Cited by
-
Vitamin D and prebiotics for intestinal health in cystic fibrosis: Rationale and design for a randomized, placebo-controlled, double-blind, 2 x 2 trial of administration of prebiotics and cholecalciferol (vitamin D3) (Pre-D trial) in adults with cystic fibrosis.Contemp Clin Trials Commun. 2024 Feb 18;38:101278. doi: 10.1016/j.conctc.2024.101278. eCollection 2024 Apr. Contemp Clin Trials Commun. 2024. PMID: 38435430 Free PMC article.
-
Vitamin D and Prebiotics for Intestinal Health in Cystic Fibrosis: Rationale and design for a randomized, placebo-controlled, double-blind, 2 × 2 trial of administration of prebiotics and cholecalciferol (vitamin D3) (Pre-D Trial) in adults with cystic fibrosis.medRxiv [Preprint]. 2024 Jan 5:2024.01.04.24300860. doi: 10.1101/2024.01.04.24300860. medRxiv. 2024. Update in: Contemp Clin Trials Commun. 2024 Feb 18;38:101278. doi: 10.1016/j.conctc.2024.101278. PMID: 38343811 Free PMC article. Updated. Preprint.
-
Vitamin D status in children with a psychiatric diagnosis, autism spectrum disorders, or internalizing disorders.Front Psychiatry. 2022 Sep 14;13:958556. doi: 10.3389/fpsyt.2022.958556. eCollection 2022. Front Psychiatry. 2022. PMID: 36186854 Free PMC article.
-
Calcifediol for Use in Treatment of Respiratory Disease.Nutrients. 2022 Jun 13;14(12):2447. doi: 10.3390/nu14122447. Nutrients. 2022. PMID: 35745177 Free PMC article. Review.
-
Vitamin D intoxication in patients with cystic fibrosis: report of a single-center cohort.Sci Rep. 2021 Apr 8;11(1):7719. doi: 10.1038/s41598-021-87099-w. Sci Rep. 2021. PMID: 33833284 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical